Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

1,062 results

• EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 6NCT01186328
• FACT CLBP 1Independent statistical analysis of Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee: primary endpoint results, effect estimate with…Phase 3Results postedn = 63NCT03285646
• FACT OA1Complete statistical analysis of the phase 3 FACT OA1 trial of fasinumab versus placebo and naproxen for pain from osteoarthritis of the knee or hip, including trial design, WOMAC endpoints, mixed-effects modeling,…Phase 3Results postedn = 3,307NCT03161093
• FACT OA2Complete statistical analysis of FACT OA2, a randomized phase 3 trial evaluating fasinumab versus placebo and NSAIDs for pain from osteoarthritis of the knee or hip, including endpoint definitions, MMRM and Cochran-Mantel-Haenszel…Phase 3Results postedn = 1,650NCT03304379
• Fall Epidemic Viral Pediatric Study: Complete Statistical AnalysisIndependent statistical analysis of Fall Epidemic Viral Pediatric Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01192178).Phase 4Results postedn = 339NCT01192178
• Feasibility of SBIRT-PN: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of SBIRT-PN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03057119).Phase NAResults postedn = 86NCT03057119
• Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 48NCT04193605
• Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 52NCT01206777
• Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 10NCT04506086
• FEATUREIndependent statistical analysis of A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 314NCT00673920
• FINCH 1Independent statistical analysis of Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 1,759NCT02889796
• First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: Complete Statistical AnalysisIndependent statistical analysis of First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: primary endpoint results, effect estimate with confidence interval,…Phase 1Results postedn = 10NCT04075721
• First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Complete Statistical AnalysisIndependent statistical analysis of First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High…Phase 1/2Results postedn = 101NCT05086315
• First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 73NCT05163522
• FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): Complete Statistical AnalysisIndependent statistical analysis of FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 169NCT02448381
• FLEX MIndependent statistical analysis of A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 1,041NCT01198002
• FLEX VIndependent statistical analysis of A Study in Participants With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01202773).Phase 3Results postedn = 456NCT01202773
• Flex-UpIndependent statistical analysis of A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence…Phase 4Results postedn = 461NCT05507580
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 64NCT00536341
• Fluticasone Nasal Spray Patient Preference Study: Complete Statistical AnalysisIndependent statistical analysis of Fluticasone Nasal Spray Patient Preference Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00398476).Phase 3Results postedn = 127NCT00398476
• FOCUSIndependent statistical analysis of A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 315NCT01302392
• Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 26NCT01898078
• FREEDOMSIndependent statistical analysis of the FREEDOMS phase 3 trial of fingolimod in relapsing-remitting multiple sclerosis, covering randomized design, annualized relapse rate, statistical methodology, safety, and interpretation.Phase 3Results postedn = 1,272NCT00289978
• FREEDOMS IIIndependent statistical analysis of Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 1,083NCT00355134
• Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 10NCT04294641
• GAINIndependent statistical analysis of Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 194NCT04880200
• GALAComplete statistical analysis of the phase 3 GALA trial of glatiramer acetate 40 mg three times weekly versus placebo in relapsing-remitting multiple sclerosis, including trial design, relapse endpoints, MRI outcomes, statistical methodology,…Phase 3Results postedn = 1,404NCT01067521
• GammozIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 18NCT02911688
• Gardasil Vaccination in Post Stem Cell Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Gardasil Vaccination in Post Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01092195).Phase 1Results postedn = 64NCT01092195
• GAVOTTEIndependent statistical analysis of A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS): primary endpoint results, effect…Phase 3Results postedn = 769NCT04548999
• Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 14NCT00369629
• GEMINI Study – A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: Complete Statistical AnalysisIndependent statistical analysis of GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 337NCT00105079
• Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA): Complete Statistical AnalysisIndependent statistical analysis of Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03362957).Phase NAResults postedn = 21NCT03362957
• GINGERIndependent statistical analysis of Ginger's Therapeutic Potential in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03705832).Phase EARLY_1Results postedn = 54NCT03705832
• GLIDERIndependent statistical analysis of A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS): primary endpoint results, effect estimate…Phase 2Results postedn = 31NCT04700280
• Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Glucagon Response to Prandial Insulin Administration in Persons With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 1NCT04079881
• Glucose Variability in Type 1 Diabetes (T1D) and Glycaemic Responses to Food Composition.: Complete Statistical AnalysisIndependent statistical analysis of Glucose Variability in Type 1 Diabetes (T1D) and Glycaemic Responses to Food Composition.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 96NCT06546657
• Glutathione Metabolism in Adolescents With Type 1 Diabetes – Study A: Complete Statistical AnalysisIndependent statistical analysis of Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 10NCT00858897
• GO-VIVAIndependent statistical analysis of A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: primary endpoint results,…Phase 3Results postedn = 130NCT02277444
• Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): Complete Statistical AnalysisIndependent statistical analysis of Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 433NCT01004432
• GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.: Complete Statistical AnalysisIndependent statistical analysis of GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV)…Phase 3Results postedn = 429NCT00381303
• Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: Complete Statistical AnalysisIndependent statistical analysis of Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 77NCT00130286
• GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia: Complete Statistical AnalysisIndependent statistical analysis of GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia: primary endpoint results, effect estimate…Phase 3Results postedn = 709NCT01345253
• GVHD ASEDIndependent statistical analysis of A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients: primary endpoint results,…Phase 2Results postedn = 18NCT01972438
• HA vs PRPIndependent statistical analysis of Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 111NCT02588872
• HANDmacIndependent statistical analysis of A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 19NCT01449006
• HAPIIndependent statistical analysis of HIV And Parasitic Infection (HAPI) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05323396).Phase NAResults postedn = 120NCT05323396
• Haplo/CordIndependent statistical analysis of Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 1NCT01050946
• Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells: Complete Statistical AnalysisIndependent statistical analysis of Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01050764).Phase 1/2Results postedn = 10NCT01050764
• Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D): Complete Statistical AnalysisIndependent statistical analysis of Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 217NCT05413239

← All therapeutic areas